Buradasınız

Anasayfa » Content

Postoperatif Radyoterapi İle Eş Zamanlı Kapesitabin Uygulanan Lokal İleri Evre Rektum Kanserli Olgularda Etkinlik ve Tolerabilite Değerlendirilmesi

The Evaluation of Efficacy and Tolerability of Postopertative Concomittant Chemoradiation With Capecitabine in Cases With Locally Advanced Rectal Cancer

Journal Name:

  • Uludağ Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2009

Key Words:

Keywords (Original Language):

Author Name
Abstract (2. Language): 
The purpose of this study was to evaluate the efficacy and the toxicity of concomitant chemoradiotherapy (CRT) with capecitabine in cases with locally advanced rectal cancer. 26 cases with stage II-III rectal adenocarcinoma, treated with postoperative CRT with capecitabine at Uludag University Faculty of Medicine Radiotherapy Center, between March 2004-January 2007, were evaluated retrospectively. The radiotherapy was delivered with a boost dose of 50.4-54 Gray (Gy) totally and capecitabine was given median 1650 mg/m²/day (range, 1300- 1650). The median 2- year overall survival (OS) was 80%, and during the median follow-up time of 19 months (range, 1-30) there was no locoregional recurrence. Grade 3 leucopenia and diarrhea were observed in one (4%) and two (8%) cases, respectively. Although the insufficiency of follow-up time and the number of cases, we concluded that the concomitant postoperative chemoradiotherapy with capecitabine may be an effective and tolerabl treatment in locally advanced rectal cancer.
Bookmark/Search this post with
Abstract (Original Language): 
Çalışmanın Amacı lokal ileri evre rektum kanserli olgularda postoperatif radyoterapi (RT) ile eş zamanlı kapesitabin uygulanmasının etkinli- ğini ve tolere edilebilirliğini değerlendirmektir. Mart 2004-Ocak 2007 tarihleri arasında Uludağ Üniversitesi Tıp Fakültesi Radyoterapi Merkezi’nde postoperatif radyoterapi ile eş zamanlı kapesitabin uygulanan evre II-III rektum adenokarsinomlu 26 olgu retrospektif değerlendirildi. Olgulara RT boost dozu ile birlikte toplam 50.4- 54 Gray (Gy), kapesitabin ortanca 1650 mg/m²/gün (minimum-maksimum : 1300- 1650) dozda uygulandı. Ortanca iki yıllık genel sağkalım (GSK) oranı %80 olup, ortanca 19 aylık (minimum-maksimum: 1-30) izlem süresinde hiçbir olguda lokal yineleme görülmedi. Grade 3 lökopeni ve diyare sırasıyla bir (%4) ve iki (%8) olguda gözlendi. İzlem süresi ve olgu sayısının yetersizliğine rağmen lokal ileri evre rektum kanserinde radyoterapi ile eş zamanlı kapesitabin uygulanımı etkin ve tolere edilebilir olması nedeniyle alternatif tedavi olarak önerilebilir.
FULL TEXT (PDF): 
PDF icon arastirmax-postoperatif-radyoterapi-ile-es-zamanli-kapesitabin-uygulanan-lokal-ileri-evre-rektum-kanserli-olgularda-etkinlik-tolerabilite-degerlendirilmesi.pdf
  • 1
21-25
  • Turkish

REFERENCES

References: 

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics,
1998. CA Cancer J Clin 1998; 48: 6-29.
2. Balch GC, De Meo A, Guillem JG. Modern management of
rectal cancer. World J Gastrenterol 2006; 28; 12: 3186-95.
3. Prolongation of the disease free interval in surgically treated
rectal carcinoma: Gastrointestinal Tumor Study Group. N Engl
J Med 1985; 312: 1465-72
4. Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical
adjuvan therapy for high-risk rectal carcinoma. N Engl J Med
1991; 324: 709-15.
5. Adjuvant radiotherapy for rectal cancer: a systematic overview
of 8, 507 patients from 22 randomised trials. Colorectal Cancer
Collaborative Group. Lancet 2001; 358: 1291-304.
6. Fleshman JW, Myerson RJ. Adjuvant RT for adenocarcinoma
of the rectum. Surgical Clinics of North America 1997; 77: 15-
25.
7. Willet CG, Teper JE, Kaufman DS, et al.Adjuvant
postoperative radiation therapy for rectal adenocarcinoma. Am
J Clin Oncol 1992; 15: 371-5.
8. Cummings BJ. Adjuvant radiation therapy for colorectal cancer.
Cancer Suppl. 1992; 70: 1372-83.
9. Prolongation of the disease-free interval in surgically treated
rectal carcinoma. Gastrointestinal Tumor Study Group. N Engl
J Med 1985; 312: 1465-72.
10. NIH Consensus Development Conference: adjuvant therapy for
patients with colon and rectal cancer. JAMA 1990; 264: 1444–
50.
11. Grem JL. Systemic treatment options in advanced colorectal
cancer: Perspectives on combination 5-fluorouracil plus
leucovorin. Semin Oncol 1997; 24 (Suppl.18): 8-18.
12. Payne SA. A study of quality of life in cancer patients receiving
palliative chemotherapy. Soc Sci Med 1992; 35: 1505-9.
13. Miwa M, Ura M, Nishida M, et al. Design of a novel oral
fluoropyrimidine capecitabine, wich generates 5-Fluorouracil
selectivly in tumours by enzyms concentreated in human liver
and cancer tissue . Eur J Cancer 1998; 34: 1274-81.
14. Hoff PM, Ansari R, Batist G, et al. Comparison of oral
capecitabine versus intravenous fluorouracil plus leucovorin as
first-line treatment in 605 patients with metastatic colorectal
cancer: Results of a randomized phase III study. J Clin Oncol
2001; 19: 2282-92.
15. Cutsem EV, Twelves C, Cassidy J, et al. Oral capecitabine
compared with intravenous fluorouracil plus leucovorin in
patients with metastatic colorectal cancer: Results of a large
phase III study. J Clin Oncol 2001; 19: 4097-4106.
16. Cutsem EV, Hoff PM, Harper P, et al. Oral capecitabine vs
intravenous 5-fluorouracil and leucovorin: Integrated efficacy
data and novel analyses from two large, randomized, phase III
trials. Br J Cancer 2004; 90: 1190-7.
17. Dunst J, Reese T, Sutter T, et al. Phase I trial evaluating the
concurrent combination of radiotherapy and capecitabine in
rectal cancer. J Clin Oncol 2002; 20: 3983-91.
18. Kim JS, Cho MJ, Song KS, et al. Preoperative chemoradiation
using oral capecitabine in LARC. Int J Radiat Oncol Biol Phys
2002; 54: 403-8.
19. Kim JC, Kim TW, Kim JH, et al. Preoperative concurrent
radiotherapy with capecitabine before total mesorectal excision
in LARC. Int J Radiat Oncol Biol Phys 2005; 63: 346-53.
20. De Paoli A, Chiara S, Luppi G, et al. Capecitabine in
combination with preoperative radiation therapy in locally
advanced, resectable, rectal cancer: A multicentric phase II
study. Ann Oncol 2006; 17: 246-51.
21. Souglakos J, Androulakis N, Kakolyris S, et al. Multicenter
dose-finding study of concurrent capecitabine and radiotherapy
as adjuvant treatment for operative rectal cancer. Int J Radiat
Oncol Biol Phys 2003; 56: 1284-7.
22. Jin J, Lin YX, Liu YP, et al. A phase I study of concurrent
radiotherapy and capecitabine as adjuvant treatment for
operable rectal cancer. Int J Radiat Oncol Biol Phys 2006; 64:
725-9.
23. Colon and rectum. In: American Joint Committee on Cancer:
AJCC Cancer Staging Manual. 6th ed. New York, NY:
Springer, 2002; 113-24.
24. Willett CG, Tepper JE, Cohen AM, et al. Failure patterns
following curative resection of colonic carcinoma. Ann Surg
1984; 200: 685-90.
25. Rich T, Gunderson LL, Lew R, et al. Patterns of recurrence of
rectal cancer after potentially curative surgery. Cancer 1983;
52: 1317-29.
26. Kapiteijn E, van de Velde CJ. European trials with total
mesorectal excision. Semin Surg Oncol 2000; 19: 350-7.
27. Das P, Lin EH, Bhatia S, et al. Preoperative chemoradiotherapy
with capecitabine versus protracted infusion 5-Fluorouracil for
rectal cancer: A matched-pair analysis. Int J Radiat Oncol Biol
Phys 2006; 66: 1378-83.
28. Twelves C, Wong A, Nowacki MP, et al. Capecitabine as
adjuvant treatment for stage III colon cancer. N Engl J Med
2005; 352: 2696-704.
29. .Berg D. Managing the side effects of chemotherapy for
colorectal cancer. Semin Oncol 1998; 25: 53-9.
30. Krishnan S, Janjan NA, Skibber JM, et al. Phase II study
ofcapecitabine (Xeloda) and concomitant boost radiotherapy in
patients with locally advanced rectal cancer. Int J Radiat Oncol
Biol Phys 2006; 66: 762-71.
31. Dalton P, Chandrosoma P: Gastrointestinal Pathology. In:
Chondrosarcoma P. Colorectal Malignant Neoplasm. 1st ed,
Stamford Connecticut: Appleton & Lange; Los Angeles, 1999:
339-65.
32. Symonds DA, Vickery AJ. Mucinous carcinoma of colon and
rectum. Cancer 1976; 37: 1891-990.

Thank you for copying data from http://www.arastirmax.com